Ana B. Oton

Oncology
777 Bannock St # 7782
Denver, CO 80204

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 24, 2026

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 20, 2025

The impact of desmoid tumors: insights from the Desmoid Tumor Research Foundation Natural History Study, 2017-2023.

The impact of desmoid tumors: insights from the Desmoid Tumor Research Foundation Natural History Study, 2017-2023.

Journal: Orphanet journal of rare diseases
Published: September 30, 2024

Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.

Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.

Journal: Cancer
Published: February 02, 2024

Disease and economic burden of surgery in desmoid tumors: a review.

Disease and economic burden of surgery in desmoid tumors: a review.

Journal: Expert review of pharmacoeconomics & outcomes research
Published: April 26, 2023

Desmoid Tumors: A Comprehensive Review.

Desmoid Tumors: A Comprehensive Review.

Journal: Advances in therapy
Published: April 25, 2023

Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States.

Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States.

Journal: Current medical research and opinion
Published: December 18, 2020

Debunking Myths While Understanding Limitations.

Debunking Myths While Understanding Limitations.

Journal: American journal of public health
Published: April 09, 2020

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.

Journal: ESMO open
Published: July 18, 2019

Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice.

Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice.

Journal: Future oncology (London, England)
Published: February 23, 2019

Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy.

Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy.

Journal: The patient
Published: August 22, 2018

Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States.

Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States.

Journal: Journal of medical economics
Published: April 21, 2018
Showing 1-12 of 21

Last Updated: 09/26/2026